The present study was undertaken with an aim to formulate enteric coated tablets of Tenatoprazole (a novel proton pump inhibitor with an imidazopyridine ring) to improve bioavailability by avoiding degradation. Different core tablets were prepared using approved excipients by direct compression method and evaluated for different parameters like hardness, thickness, friability and disintegration time. Sub-coating was done for optimized formulation (F5) by using HPMC 5 cps with buildup of 3% w/w and finally enteric coating was done by using HPMCP, Eudragit L30 D55 and HPMC Acetate succinate (HPMCAS) with an average weight buildup of 5%, 8% and 10% w/w. all formulations were evaluated for different parameters like hardness, friability, thickne...
Pantoprazole is a proton pump inhibitor, belongs to group of benzimidazole, Pantoprazole sodium were...
The research focuses on the development of multiparticulate delivery system for acid-labile Lansopra...
In the present study an attempt has been taken to develop esomeprazole sustained release matrix tabl...
Pantoprazole is a proton pump inhibitor, belongs to group of benzimidazole, Pantoprazole sodium were...
Abstract: Pantoprazole is a proton pump inhibitor, belonging to the group of benzimidazoles and is u...
In an effort to reduce production costs, a simple, direct compression delayed release formulation co...
The objective of the present study is to formulate and evaluate enteric coated delayed release pelle...
The present work was aimed to development of controlled release formulations of Esomeprazole to impr...
Oral modified release multiple unit dosage forms have always been more effective therapeutic alterna...
ABSTRACT Ilaprazole is a Proton Pump Inhibitor (PPI), an anti-acidic drugused in the treatment of d...
Enteric coatings present surfaces that have low permeability in the low pH environments of the stoma...
The aim of the present study is to formulate and evaluate the pantoprazole sodium enteric coated tab...
The aim of the contemporary research work was to develop the controlled release tablets of esomepraz...
proton pump inhibitor belongs to group of benzimidazole. This compound inhabits gastric acid formati...
Background: A proton pump inhibitor is an acid labile drug which degrades at stomach pH 1.2. Delayed...
Pantoprazole is a proton pump inhibitor, belongs to group of benzimidazole, Pantoprazole sodium were...
The research focuses on the development of multiparticulate delivery system for acid-labile Lansopra...
In the present study an attempt has been taken to develop esomeprazole sustained release matrix tabl...
Pantoprazole is a proton pump inhibitor, belongs to group of benzimidazole, Pantoprazole sodium were...
Abstract: Pantoprazole is a proton pump inhibitor, belonging to the group of benzimidazoles and is u...
In an effort to reduce production costs, a simple, direct compression delayed release formulation co...
The objective of the present study is to formulate and evaluate enteric coated delayed release pelle...
The present work was aimed to development of controlled release formulations of Esomeprazole to impr...
Oral modified release multiple unit dosage forms have always been more effective therapeutic alterna...
ABSTRACT Ilaprazole is a Proton Pump Inhibitor (PPI), an anti-acidic drugused in the treatment of d...
Enteric coatings present surfaces that have low permeability in the low pH environments of the stoma...
The aim of the present study is to formulate and evaluate the pantoprazole sodium enteric coated tab...
The aim of the contemporary research work was to develop the controlled release tablets of esomepraz...
proton pump inhibitor belongs to group of benzimidazole. This compound inhabits gastric acid formati...
Background: A proton pump inhibitor is an acid labile drug which degrades at stomach pH 1.2. Delayed...
Pantoprazole is a proton pump inhibitor, belongs to group of benzimidazole, Pantoprazole sodium were...
The research focuses on the development of multiparticulate delivery system for acid-labile Lansopra...
In the present study an attempt has been taken to develop esomeprazole sustained release matrix tabl...